Pfizer nabs extra time with blockbuster Celebrex patent

By Tracy Staton Thank you, U.S. patent office. Pfizer ($PFE) won an extra 18 months of exclusivity for its pain drug Celebrex, in the form of a reissued patent that doesn’t ...

Generics bite primary-care sales, but specialty drugs soar 18.4%

By Tracy Staton Suffering Big Pharma well knows that primary-care drug spending slumped in the U.S. last year. That’s the patent cliff at work. But now, there’s a number ...

Bayer, J&J’s Xarelto again falls short in bid for ACS use

By Tracy Staton Persistence may be a virtue, but it doesn’t always pay. Johnson & Johnson ($JNJ) and Bayer tried again to persuade FDA on a new use for Xarelto, in patients ...

Longtime Roche chairman is stepping aside. Who’s up next?

By Tracy Staton There will be room at the top of Roche next year. Chairman Franz Humer will stand down after the Swiss drugmaker’s 2014 annual meeting, after 16 years as CEO ...

EC promises $187M for ambitious effort to spawn 200 new rare disease drugs

By John Carroll A few days ago the European Commission mapped out a plan to help spur development of 200 new treatments for rare diseases by the year 2020. And the Commission put ...

Celgene buys into upstart’s new approach to picking cancer combos

By John Carroll Fast-moving Celgene has turned to Presage Biosciences to begin testing the potential of cancer drug combinations in animals, paying $5 million upfront to support the ...

AstraZeneca severs ties to Alzheimer’s drug from troubled Targacept

By Ryan McBride AstraZeneca has further culled the ranks of its experimental CNS meds. The London-based drug giant ($AZN) cut ties with two programs from its U.S. partner Targacept ...

Depomed slams brakes on hot-flash drug after FDA advisers vote to reject

By John Carroll Depomed ($DEPO) took a 10% hit on its stock price mid-day Monday after FDA advisers turned thumbs down on the company’s drug to ease symptoms of hot flashes in ...

Specialty med price shock rattles ill-equipped payers

By John Carroll For the past 20 years Express Scripts ($ESRX) has been crunching the numbers on the ever rising amount of money Americans spend on drugs. But last year, the analysts ...

Avedro’s vision-correction devices hook $43M Series D

By Mark Hollmer Avedro, armed with $43 million in new Series D financing, will plow ahead with international sales expansion, U.S. regulatory trials and “aggressive” research ...

Budget battles hold new FDA user fees hostage

By Mark Hollmer Congressional budget battles are holding hostage millions of additional dollars the medical device industry agreed to pay in new FDA user fees to help fund an improved, ...

GOP cadre fears device tax could target smartphones, tablets and apps

By Mark Hollmer You may not think that the Affordable Care Act will have much of an effect on smartphones, tablets and apps. But 6 Republican U.S. representatives fear that the health ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS